Year: 2023

On track to achieve production guidance with a solid start to Q4 (All amounts expressed in U.S. Dollars unless otherwise stated) TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) reports the Company’s financial and operational results for the three- and nine-month periods ended September 30, 2023. Senior management of Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the quarterly results. Jody Kuzenko, President & CEO of Torex, stated: “We expect to close out 2023 on a solid note with the fourth quarter forecast to be the strongest quarter of production, driven by higher open pit grades now that the period of elevated waste stripping is behind us. Our confidence in achieving full year production guidance of 440,000 to 470,000 ounces (“oz”)...

Net Revenue up 23%, with Strong Subscription-Based Revenue Growth LAS VEGAS, Nov. 14, 2023 (GLOBE NEWSWIRE) — Healthy Extracts Inc. (OTCQB: HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the three and nine months ended September 30, 2023. All comparisons are to the year-ago period unless otherwise noted. Financial & Operational HighlightsNet revenue increased 23% to $614,000 in the third quarter of 2023 and was up 27% to $1.8 million for the first nine months of 2023, driven by product line and distribution channel expansion, as well as growth in subscription-based revenue. Gross margin improved to 80.4% in the third quarter from 48.4% in the...

– Expanded executive team as Lourie Zak appointed Chief Financial Officer –  – Extended clinical focus on systemic administration in small cell lung cancer – – $29.9 million in cash and equivalents – WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) —  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates. “The third quarter was highlighted by continued expansion of our executive team while advancing our pivotal Phase 3 study in platinum resistant/refractory ovarian cancer. Additionally, our small cell lung cancer trial is progressing,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Looking ahead, we remain focused on our ongoing trials, including...

BOISE, Idaho, Nov. 14, 2023 (GLOBE NEWSWIRE) — PCS Edventures!, Inc. (PCSV), a leading provider of K-12 Science, Technology, Engineering and Mathematics (STEM) education programs and drone products, today announced unaudited results of operations for its second quarter of Fiscal Year 2024 which ended on September 30, 2023. Revenue was $3.77 million, a quarterly record for the Company, up from $1.24 million in revenue for the same period last year. Net income was $1.81 million, also a quarterly record, up from $0.17 million for the same period last year. The Company ended the quarter with $2.12 million in cash. Mike Bledsoe, President, commented, “This record quarter was driven in large part by our Air Force and Iowa relationships. Excluding the revenue associated with those relationships during the quarter, our revenue would have...

SAN DIEGO, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) — via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announces financial results for the third quarter ended September 30, 2023. During the quarter, the Company continued its plan to initiate first-in-human studies of Sigyn TherapyTM and further advanced its endeavors to develop pipeline technologies to enhance the performance of cancer therapies. The initial treatment indication of Sigyn TherapyTM is being directed toward end-stage renal disease (ESRD) patients with endotoxemia, a condition that is highly prevalent and associated with increased mortality in the ESRD population.  The Company has identified three clinical site locations and is working with principal investigators to finalize the study...

Revenue of $66.2 million for Q3 2023 and $225.6 million for YTD 2023 Gross profit (exclusive of depreciation and amortization) of $16.1 million for Q3 2023 and $57.7 million for YTD 2023 Net loss of $33.6 million for Q3 2023 and $61.3 million for YTD 2023 Media margin of $19.3 million for Q3 2023 and $67.2 million for YTD 2023 Adjusted EBITDA of negative $1.7 million for Q3 2023 and positive $4.3 million for YTD 2023 Adjusted net loss of $4.1 million for Q3 2023 and $6.8 million for YTD 2023NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the third quarter ended September 30, 2023. Don Patrick, Fluent’s Chief Executive Officer, commented, “Our third quarter results clearly reflect our post-FTC settlement transition...

Reports Eleventh Consecutive Quarter of Positive Adjusted EBITDA The Botanist Danbury Dispensary in Connecticut Achieves Highest Company-wide Sales with 64% Year-Over-Year Growth Delivered record wholesale sales in New Jersey with the Company’s large-scale infrastructure project at the Egg Harbor Township, NJ facility nearing completion   NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage” or the “Company”) (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), a vertically integrated, multi-state operator of cannabis cultivation and retailing facilities in the U.S., today reported its financial results for the third quarter ended September 30, 2023 (“Q3 2023”). Third Quarter 2023 Financial HighlightsConsolidated revenue of $56.5 million, a decrease of 2.8% compared to the quarter ended June 30, 2023 (“Q2 2023”). Gross...

LONGVIEW, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) — Friedman Industries, Incorporated (NYSE American: FRD) announced today its results of operations for the quarter ended September 30, 2023. September 30, 2023 Quarter Highlights:Net earnings of approximately $3.5 million Sales of approximately $130.7 million 10% increase in sales volume over prior year quarter volume Working capital balance at quarter-end of approximately $129.9 million“Our second quarter results are a testament to our team’s ability to evaluate challenging market conditions and make the appropriate decisions to deliver increased sales volume and profitable results in periods of significant headwinds to profitability,” said Michael J. Taylor, President and Chief Executive Officer. “We experienced a significant decline in steel prices entering the second quarter...